CUR Neuralstem, Inc.

4.81
0  -2%
Previous Close 4.91
Open 4.88
Price To book 4.79
Market Cap 53.13M
Shares 11,045,000
Volume 58,027
Short Ratio 2.10
Av. Daily Volume 230,202

SEC filingsSee all SEC filings

  1. 8-K - Current report 17769982
  2. 8-K - Current report 17760802
  3. 8-K - Current report 17757766
  4. 8-K - Current report 17728142
  5. 8-K - Current report 17709591

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Ongoing.
NSI-566
Motor deficits due to ischemic stroke
Phase 1b to be initiated 2016
NSI-189
Cognitive deficit in schizophrenia
Phase 2 data are due 3Q 2017.
NSI-189
Major depressive disorder
Phase 2 data released early March 2015. A larger controlled Phase 2 trial is dependent on funding
NSI-566
Amyotrophic lateral sclerosis (Lou Gehrig's)

Latest News

  1. ETFs with exposure to Neuralstem, Inc. : April 19, 2017
  2. Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
  3. Neuralstem, Inc. :CUR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
  4. Neuralstem Reports Year End 2016 Fiscal Results and Business Update
  5. Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21
  6. Today's Research Reports on Market Movers: Neuralstem and Real Goods Solar
  7. Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury
  8. Neuralstem to Present at 29th Annual ROTH Conference
  9. Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
  10. Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
  11. Neuralstem, Inc. (CUR) Is Up. Here’s Why And What It Means
  12. Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis
  13. Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
  14. Neuralstem to Present at BIO CEO & Investor Conference
  15. ETFs with exposure to Neuralstem, Inc. : January 19, 2017
  16. Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments

SEC Filings

  1. 8-K - Current report 17769982
  2. 8-K - Current report 17760802
  3. 8-K - Current report 17757766
  4. 8-K - Current report 17728142
  5. 8-K - Current report 17709591
  6. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17708127
  7. 8-K - Current report 17700162
  8. 8-K - Current report 17682944
  9. 8-K - Current report 17647215
  10. SC 13D - General statement of acquisition of beneficial ownership 17641409